Compare URG & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | URG | CADL |
|---|---|---|
| Founded | 2004 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 699.3M | 578.8M |
| IPO Year | 2006 | 2021 |
| Metric | URG | CADL |
|---|---|---|
| Price | $1.57 | $8.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $2.57 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 7.8M | 2.1M |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.62 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,207,000.00 | $125,000.00 |
| Revenue This Year | $200.42 | N/A |
| Revenue Next Year | $98.46 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.74 | $4.35 |
| 52 Week High | $2.35 | $9.27 |
| Indicator | URG | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 42.85 | 58.29 |
| Support Level | $1.42 | $4.91 |
| Resistance Level | $1.74 | $9.27 |
| Average True Range (ATR) | 0.12 | 0.65 |
| MACD | -0.04 | -0.12 |
| Stochastic Oscillator | 19.44 | 30.53 |
Ur-Energy Inc is engaged in uranium mining and recovery operations, with activities including the acquisition, exploration, development, and production of uranium mineral resources located in Wyoming. The company owns and operates the Lost Creek in-situ recovery uranium facility in south-central Wyoming, Lost Creek received an amendment to its license allowing the expansion of mining activities within the existing Lost Creek Project and the adjacent LC East Project; Shirley Basin; Other U.S. Projects.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.